Histoculture 药敏试验预测卵巢癌铂类敏感性和预后的适用性。
Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer.
机构信息
Department of Obstetrics and Gynecology, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
Department of Obstetrics and Gynecology, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
出版信息
Anticancer Res. 2021 Dec;41(12):6287-6292. doi: 10.21873/anticanres.15450.
BACKGROUND/AIM: To retrospectively analyze the results of histoculture drug response assays (HDRAs) to determine whether the results could predict platinum sensitivity and prognosis in ovarian cancer.
PATIENTS AND METHODS
One hundred thirty-nine patients with ovarian cancer were reviewed. HDRAs were conducted for platinum and taxane agents. Platinum resistance and sensitivity occurred in 21 and 118 patients, respectively. To analyze the relationship between the inhibition rates (IRs) of tumor growth caused by the platinum agent and clinical outcomes, Student's t-test and linear regression analysis were used.
RESULTS
We found that the average IRs of the platinum and taxane agent were not statistically significant between the platinum-sensitive and - resistant groups. There was no statistical significance for overall survival, progression-free survival, or platinum-free interval.
CONCLUSION
The HDRA is not useful for predicting platinum sensitivity and survival outcomes.
背景/目的：回顾性分析组织培养药物反应分析（HDRAs）的结果，以确定其是否能预测卵巢癌对铂类药物的敏感性和预后。
患者与方法
共回顾了 139 名卵巢癌患者。对铂类药物和紫杉烷类药物进行 HDRAs 检测。分别有 21 名和 118 名患者对铂类药物耐药和敏感。为分析铂类药物引起的肿瘤生长抑制率（IR）与临床结局的关系，采用了Student's t 检验和线性回归分析。
结果
我们发现，铂类药物敏感组和耐药组之间，铂类药物和紫杉烷类药物的平均 IR 无统计学差异。铂类药物无进展生存期、总生存期或无铂间期也无统计学意义。
结论
HDRAs 对于预测铂类药物敏感性和生存结局没有帮助。
Zotero 插件